Alemtuzumab in the treatment of multiple sclerosis

Óscar Fernandez Institute of Clinical Neuroscience, Neurology Department, Hospital Regional Universitario Carlos Haya, FIMABIS, Malaga, Spain Abstract: Alemtuzumab (formerly known as Campath-1H) has recently been approved by the European Medicines Agency for highly-active, relapsing-rem...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Fernandez Ó
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/74a7d160c74b48a585fc912165f59d34
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:74a7d160c74b48a585fc912165f59d34
record_format	dspace
spelling	oai:doaj.org-article:74a7d160c74b48a585fc912165f59d342021-12-02T02:30:22ZAlemtuzumab in the treatment of multiple sclerosis1178-7031https://doaj.org/article/74a7d160c74b48a585fc912165f59d342014-02-01T00:00:00Zhttp://www.dovepress.com/alemtuzumab-in-the-treatment-of-multiple-sclerosis-a15776https://doaj.org/toc/1178-7031 Óscar Fernandez Institute of Clinical Neuroscience, Neurology Department, Hospital Regional Universitario Carlos Haya, FIMABIS, Malaga, Spain Abstract: Alemtuzumab (formerly known as Campath-1H) has recently been approved by the European Medicines Agency for highly-active, relapsing-remitting multiple sclerosis (MS). The molecule targets the CD52 surface glycoprotein on certain T cells and B cells and is thought to exert its effect in MS through a “resetting” of the lymphocyte population. Approval was granted on the strength of two pivotal studies, Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis (CARE-MS)-1 in the first-line setting and CARE-MS-2 in patients who had failed first-line therapy. In both studies, alemtuzumab significantly reduced the relapse rate compared to the comparator, interferon beta-1a (44 µg) given subcutaneously three-times per week (Rebif®). In the first-line study, alemtuzumab was also found to significantly reduce the number of patients with sustained progression compared to interferon beta-1a therapy. Autoimmune disorders represent the major side effect of alemtuzumab therapy although they can be managed by careful monitoring and early treatment. Overall, alemtuzumab is likely to be a valuable addition to the neurologist´s armamentarium for the treatment of relapsing-remitting MS. Keywords: alemtuzumab, multiple sclerosis, new therapies, interferon beta-1a, monoclonal antibody, treatmentFernandez ÓDove Medical PressarticlePathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol 2014, Iss default, Pp 19-27 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Fernandez Ó Alemtuzumab in the treatment of multiple sclerosis
description	Óscar Fernandez Institute of Clinical Neuroscience, Neurology Department, Hospital Regional Universitario Carlos Haya, FIMABIS, Malaga, Spain Abstract: Alemtuzumab (formerly known as Campath-1H) has recently been approved by the European Medicines Agency for highly-active, relapsing-remitting multiple sclerosis (MS). The molecule targets the CD52 surface glycoprotein on certain T cells and B cells and is thought to exert its effect in MS through a “resetting” of the lymphocyte population. Approval was granted on the strength of two pivotal studies, Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis (CARE-MS)-1 in the first-line setting and CARE-MS-2 in patients who had failed first-line therapy. In both studies, alemtuzumab significantly reduced the relapse rate compared to the comparator, interferon beta-1a (44 µg) given subcutaneously three-times per week (Rebif®). In the first-line study, alemtuzumab was also found to significantly reduce the number of patients with sustained progression compared to interferon beta-1a therapy. Autoimmune disorders represent the major side effect of alemtuzumab therapy although they can be managed by careful monitoring and early treatment. Overall, alemtuzumab is likely to be a valuable addition to the neurologist´s armamentarium for the treatment of relapsing-remitting MS. Keywords: alemtuzumab, multiple sclerosis, new therapies, interferon beta-1a, monoclonal antibody, treatment
format	article
author	Fernandez Ó
author_facet	Fernandez Ó
author_sort	Fernandez Ó
title	Alemtuzumab in the treatment of multiple sclerosis
title_short	Alemtuzumab in the treatment of multiple sclerosis
title_full	Alemtuzumab in the treatment of multiple sclerosis
title_fullStr	Alemtuzumab in the treatment of multiple sclerosis
title_full_unstemmed	Alemtuzumab in the treatment of multiple sclerosis
title_sort	alemtuzumab in the treatment of multiple sclerosis
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/74a7d160c74b48a585fc912165f59d34
work_keys_str_mv	AT fernandezoacute alemtuzumabinthetreatmentofmultiplesclerosis
_version_	1718402415349202944

Alemtuzumab in the treatment of multiple sclerosis

Ejemplares similares